193 related articles for article (PubMed ID: 37214845)
1. Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct.
Kosno M; Currie SL; Kumar A; Xing C; Rosen MK
bioRxiv; 2023 May; ():. PubMed ID: 37214845
[TBL] [Abstract][Full Text] [Related]
2. Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct.
Kosno M; Currie SL; Kumar A; Xing C; Rosen MK
Sci Rep; 2023 Jul; 13(1):11907. PubMed ID: 37488172
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
4. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
[TBL] [Abstract][Full Text] [Related]
5. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
[TBL] [Abstract][Full Text] [Related]
6. Supercharging BRD4 with NUT in carcinoma.
Eagen KP; French CA
Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
[TBL] [Abstract][Full Text] [Related]
7. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
8. NUT Is a Driver of p300-Mediated Histone Hyperacetylation: From Spermatogenesis to Cancer.
Rousseaux S; Reynoird N; Khochbin S
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565363
[TBL] [Abstract][Full Text] [Related]
9. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
[TBL] [Abstract][Full Text] [Related]
11. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
[TBL] [Abstract][Full Text] [Related]
12. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
[TBL] [Abstract][Full Text] [Related]
13. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
Yan J; Diaz J; Jiao J; Wang R; You J
J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
[TBL] [Abstract][Full Text] [Related]
14. Interplay of condensation and chromatin binding underlies BRD4 targeting.
Strom AR; Eeftens JM; Polyachenko Y; Weaver CJ; Watanabe HF; Bracha D; Orlovsky ND; Jumper CC; Jacobs WM; Brangwynne CP
Mol Biol Cell; 2024 Jun; 35(6):ar88. PubMed ID: 38656803
[TBL] [Abstract][Full Text] [Related]
15. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.
Reynoird N; Schwartz BE; Delvecchio M; Sadoul K; Meyers D; Mukherjee C; Caron C; Kimura H; Rousseaux S; Cole PA; Panne D; French CA; Khochbin S
EMBO J; 2010 Sep; 29(17):2943-52. PubMed ID: 20676058
[TBL] [Abstract][Full Text] [Related]
16. miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein.
Tonouchi E; Gen Y; Muramatsu T; Hiramoto H; Tanimoto K; Inoue J; Inazawa J
Sci Rep; 2018 Mar; 8(1):4482. PubMed ID: 29540837
[TBL] [Abstract][Full Text] [Related]
17. "Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
Shiota H; Elya JE; Alekseyenko AA; Chou PM; Gorman SA; Barbash O; Becht K; Danga K; Kuroda MI; Nardi V; French CA
Mol Cancer Res; 2018 Dec; 16(12):1826-1833. PubMed ID: 30139738
[TBL] [Abstract][Full Text] [Related]
18. BRD4-targeting PROTAC as a unique tool to study biomolecular condensates.
Shi Y; Liao Y; Liu Q; Ni Z; Zhang Z; Shi M; Li P; Li H; Rao Y
Cell Discov; 2023 May; 9(1):47. PubMed ID: 37156794
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the Role of microRNAs in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma.
Pathak E; Bhavya ; Mishra D; Atri N; Mishra R
Bioinformation; 2017; 13(6):209-213. PubMed ID: 28729764
[TBL] [Abstract][Full Text] [Related]
20. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
